111 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
15 Feb 24
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:03am
; Agios’ strategic vision and goals, including its key milestones for 2024; and the potential benefits of Agios’ strategic plans and focus. The words … , goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
development, including PYRUKYND®, AG-946, its PAH stabilizer and its novel siRNA Targeting TMPRSS6; Agios’ strategic vision and goals, including its key … ’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
development, including PYRUKYND®, AG-946 and its PAH stabilizer; Agios’ strategic vision and goals, including its key milestones for 2024 and potential … , operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical
8-K
EX-99.1
z0br pnin
2 Nov 23
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
7:02am
8-K
EX-99.1
vceght83v8h5y
3 Aug 23
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
6:38am
S-8
EX-99.1
lck98wzhdjpz
13 Jun 23
Registration of securities for employees
4:13pm
8-K
EX-99.1
6dclo0m
4 May 23
Agios Reports Business Highlights and First Quarter 2023 Financial Results
7:03am
8-K
fxo4w1flwv5vn998
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
8-K
EX-99.1
1ajjpj
6 Dec 22
Agios Appoints Tsveta Milanova as Chief Commercial Officer
7:37am
8-K
EX-99.1
9t27s qpr9b5v
3 Nov 22
Agios Reports Business Highlights and Third Quarter 2022 Financial Results
7:02am
8-K
EX-99.1
fuojc89se4m1
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
S-8
EX-99.3
nuxa8e0us0f4bkl dvu
26 Sep 22
Registration of securities for employees
5:19pm